In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in ...

Formal triggers to reassess, restrict, or withdraw accelerated approvals are urged when postmarketing confirmatory trials lag ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

With the patent cliff looming, biosimilars can play an important role in the coming years. According to Newcomer, there are ...

Marking a fundamental shift in how we define acceptable clinical proof, it has indicated that one well-controlled trial, ...

In an interview with Pharmaceutical Executive, Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, ...

, is a distinguished physician and epidemiologist with extensive experience in the pharmaceutical industry, global public health, digital health innovation, ...

Co-founder and CEO of Briya, a healthcare technology company supporting vital medical and biopharma research and innovation through proprietary AI and data solut ...

IT executive with extensive business leadership, service design & delivery, and operations skills across the NA, LATAM, and Eu ...

Launch financing of $300M enables Beeline to operationalize an in-licensed immunology portfolio, with afimetoran (TLR7/8) in ...

A reverse-merger structure uses Galera’s public listing and cash to bring Obsidian public, while Madan Jagasia is slated to ...

While FDA’s draft guidance may alleviate some of the pressures when biosimilar developers, there are still other significant ...